(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 33.23% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.99%.
Iovance Biotherapeutics's revenue in 2026 is $378,983,000.On average, 12 Wall Street analysts forecast IOVA's revenue for 2026 to be $197,567,629,132, with the lowest IOVA revenue forecast at $186,075,275,181, and the highest IOVA revenue forecast at $205,354,115,323. On average, 12 Wall Street analysts forecast IOVA's revenue for 2027 to be $280,438,419,779, with the lowest IOVA revenue forecast at $257,125,226,720, and the highest IOVA revenue forecast at $302,252,610,148.
In 2028, IOVA is forecast to generate $425,837,054,083 in revenue, with the lowest revenue forecast at $326,088,603,528 and the highest revenue forecast at $600,989,041,149.